Oura is seeking up to $3bn in an IPO that would value it above $16bn

Oura is reportedly targeting a September US listing to raise up to $3bn and value the smart ring maker at more than $16bn. The valuation would be a step up from its $10.9bn mark last September, suggesting improved investor appetite and potentially supporting a re-rating for the company ahead of the IPO.

Analysis

This is less about one private listing and more about whether public markets are willing to pay software-type multiples for consumer hardware that has a recurring data layer. If the deal clears at the top end and holds, it is a positive read-through for premium wearables, especially Garmin, and for the broader thesis that health tracking can support subscription economics rather than one-time device economics. The competitive signal is more important than the company itself: incumbents will need to deepen sleep/recovery software or risk losing high-value users to lower-friction form factors.

The immediate catalyst is sentiment; the 1-3 month window is whether the book and aftermarket prove real demand, not just scarcity value. The medium-term risk is that public investors quickly reprice the story once they see hardware gross margin discipline, retention, and how much growth is actually coming from device replacement versus true category expansion. A weak first two quarterly prints would likely compress the multiple sharply even if revenue keeps growing.

Contrarian view: a rich valuation may be more a function of late-stage capital chasing than a durable public-equity signal. The market may be underestimating how easily watch OEMs and ecosystem players can copy the core use case, while overestimating the addressable market beyond early adopters. Watch for lockup overhang and any evidence that new customers are simply migrating from watches rather than expanding the total wearable pool.

Key Decisions for Investors

• Use Garmin (GRMN) as the liquid public proxy: start a tactical long only if the IPO prices inside the range and trades >10% above offer in the first 2 sessions; target 8-12% relative upside over 1-3 months. Falsifier: weak aftermarket tape or a first-quarter guide that points to slowing premium device demand.
• Do not chase broad consumer-hardware beta on the headline; wait for evidence that the market is rewarding subscription-enabled devices rather than just private-market scarcity. If the IPO breaks out, prefer a small basket long in listed health/wearable proxies over a large single-name bet.
• Set a watch item on Apple (AAPL) wearables disclosures into the next earnings cycle; if management leans harder into health/subscription services, it would confirm the competitive pressure is real. If not, the category may remain niche and the IPO premium could prove overextended.